Standout Papers
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (2001)
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome (2001)
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia (2002)
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (2007)
Immediate Impact
4 by Nobel laureates 25 from Science/Nature 154 standout
Citing Papers
Small molecules, big impact: 20 years of targeted therapy in oncology
2020 Standout
Challenges and Opportunities in Cancer Drug Resistance
2020 Standout
Works of Debra Resta being referenced
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Debra Resta | 6034 | 4335 | 3080 | 22 | 8.8k | |
| J. Ford | 4775 | 3280 | 2133 | 57 | 8.4k | |
| Nicholas Lydon | 7106 | 4730 | 3271 | 39 | 12.4k | |
| Neil P. Shah | 7097 | 5660 | 3808 | 49 | 8.6k | |
| Renaud Capdeville | 6628 | 4895 | 3245 | 49 | 12.7k | |
| Sayuri Ohno-Jones | 3712 | 2453 | 1822 | 7 | 6.1k | |
| Jürgen Thiele | 6070 | 4775 | 1736 | 71 | 8.6k | |
| Junia V. Melo | 7131 | 5468 | 3166 | 119 | 10.0k | |
| J. Zimmermann | 3260 | 2067 | 1456 | 47 | 6.1k | |
| Jianqin Shan | 6128 | 3784 | 2165 | 79 | 7.2k | |
| Elisabeth Buchdunger | 8528 | 5495 | 3895 | 59 | 17.1k |
All Works
Loading papers...